ArticleMalaria journal2025
Recrudescent severe malaria due to Plasmodium falciparum following treatment in a Taiwanese patient: a case report.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere malaria caused by Plasmodium falciparum remains a life-threatening disease, particularly in non-immune individuals returning from endemic regions. While prompt treatment can usually achieve parasite clearance, recrudescence after initial recovery is rare and presents unique diagnostic and management difficulties. This report documents a case of recrudescent severe malaria in a Taiwanese traveller, highlighting the complexity of managing in the setting of multi-organ failure, even with guideline-based therapy. CASE PRESENTATION: A previously healthy 66-year-old Taiwanese man developed fever, vomiting, diarrhoea, and jaundice shortly after returning from multiple Central African countries with high malaria prevalence. His condition rapidly deteriorated to multi-organ failure, including acute kidney injury, liver failure, thrombocytopenia, and respiratory distress. Blood smear microscopy revealed a high parasitaemia (20%) due to P. falciparum, which was confirmed by real-time PCR. MANAGEMENT AND OUTCOME: The patient received intravenous artesunate and oral artemether-lumefantrine, in addition to haemodialysis and plasma exchange as supportive therapies. Initial treatment achieved parasite clearance and clinical improvement. However, 4 weeks later, the patient experienced recrudescence with recurrent fever, anaemia, and return of parasitaemia. The therapeutic regimen was then revised to artesunate combined with doxycycline and clindamycin, followed by oral artemether-lumefantrine. This approach led to successful parasite clearance within 2 weeks and complete recovery, with no further recurrence observed during follow-up.
conclusionsThis case highlights that even with prompt, guideline-based therapy and the absence of pfk13 mutations, severe P. falciparum malaria in non-immune individuals can still develop recrudescence. Enhanced clinical vigilance, laboratory monitoring, and multidisciplinary care are essential for management. Reporting such rare recrudescent cases supports clinical awareness, informs best practice, and strengthens public health preparedness in low-incidence regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.